Microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitors are considered as potential therapeutic agents for the treatment of inflammatory pain and certain types of cancer. So far, several series of acidic as well as non-acidic inhibitors of mPGES-1 have been discovered. Acidic inhibitors, however, may have issues, such as loss of potency in human whole blood and in vivo, stressing the importance of the design and identification of novel, non-acidic chemical scaffolds of mPGES-1 inhibitors. Using a multistep virtual screening protocol, the Vitas-M compound library (∼1.3 million entries) was filtered and 16 predicted compounds were experimentally evaluated in a biological assay in vitro. This approach yielded two molecules active in the low micromolar range (IC50 values: 4.5 and 3.8 μM, respectively).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4528062 | PMC |
| http://dx.doi.org/10.1016/j.bmc.2015.05.045 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
5-methyl-2-carboxamidepyrrole-based novel dual mPGES-1/sEH inhibitors as promising anticancer candidates.
Arch Pharm (Weinheim)
January 2025
Department of Pharmacy, University of Salerno, Fisciano, Italy.
Inhibiting microsomal prostaglandin E synthase-1 (mPGES-1), an inducible enzyme involved in prostaglandin E (PGE) biosynthesis and tumor microenvironment (TME) homeostasis, is a valuable strategy for treating inflammation and cancer. In this work, 5-methylcarboxamidepyrrole-based molecules were designed and synthesized as new compounds targeting mPGES-1. Remarkably, compounds 1f, 2b, 2c, and 2d were able to significantly reduce the activity of the isolated enzyme, showing IC values in the low micromolar range.
View Article and Find Full Text PDFNovel Benzimidazole Derivatives as Potent Inhibitors of Microsomal Prostaglandin E Synthase 1 for the Potential Treatment of Inflammation, Pain, and Fever.
J Med Chem
December 2024
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Gazi University, 06560 Ankara, Turkey.
Article Synopsis
- mPGES-1 is highlighted as a key target for developing treatments for inflammation and pain, with the study introducing new benzimidazole compounds that effectively inhibit this enzyme.
- One of the compounds, AGU654, showed exceptional selectivity for mPGES-1 over other related enzymes, with a low inhibition concentration (IC = 2.9 nM) and promising bioavailability.
- AGU654 was able to reduce PGE production from activated immune cells without affecting other prostaglandins, and it also demonstrated success in alleviating fever and pain in guinea pig models, indicating its potential for managing inflammatory diseases.
Novel Synthesized Benzophenone Thiazole Hybrids Exhibited Ex Vivo and In Silico Anti-Inflammatory Activity.
Chem Biol Drug Des
October 2024
Institute of Chemistry, Federal University of Alfenas, Alfenas, Minas Gerais, Brazil.
Article Synopsis
- Novel benzophenone-thiazole hybrids were created and tested for their ability to reduce inflammation in a lab setting using human blood.
- The hybrids displayed impressive inhibition of prostaglandin E2 (PGE2) release, with some showing effectiveness comparable to existing reference drugs.
- Molecular docking studies suggest these hybrids can bind effectively to key enzymes involved in inflammation, indicating their potential as new anti-inflammatory drug candidates and emphasizing the importance of choosing the right chemical substituents.
Pivotal roles for cancer cell-intrinsic mPGES-1 and autocrine EP4 signaling in suppressing antitumor immunity.
JCI Insight
November 2024
Abramson Cancer Center, Perelman School of Medicine.
Article Synopsis
- Tumor cell-derived prostaglandin E2 (PGE2) promotes immunosuppression in the tumor microenvironment by influencing immune cells, but its specific role in tumor cells remains unexplored.
- Deleting the PGE2 synthesis enzyme or blocking its receptor (EP4) in pancreatic cancer cells activates T cells, changes the immune environment, and inhibits tumor growth.
- Combining EP4 receptor blockade with immunotherapy leads to complete tumor regressions and enhances immune memory, highlighting the importance of targeting the PGE2 signaling pathway for potential cancer treatments.
Comprehensive Analysis of the Tumour Immune Microenvironment in Canine Urothelial Carcinoma Reveals Immunosuppressive Mechanisms Induced by the COX-Prostanoid Cascade.
Vet Comp Oncol
December 2024
Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan.
A comprehensive understanding of the tumour immune microenvironment (TIME) is essential for advancing precision medicine and identifying potential therapeutic targets. This study focused on canine urothelial carcinoma (cUC) recognised for its high sensitivity to cyclooxygenase (COX) inhibitors. Using immunohistochemical techniques, we quantified the infiltration of seven immune cell populations within cUC tumour tissue to identify clinicopathological features that characterise the TIME in cUC.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!